What Is IGF-1 LR3?
Research Notice: This article covers research on IGF-1 LR3 research peptide and Hexarelin research peptide — available from Palmetto Peptides for laboratory use only.
Research Use Only Disclaimer: All peptides listed on this page are sold exclusively for in vitro and legitimate laboratory research purposes. They are not intended for human consumption, veterinary use, or any clinical application. The information in this article is for scientific and educational reference only and does not constitute medical advice. All research use must comply with applicable federal, state, and institutional regulations. Palmetto Peptides complies fully with all applicable FDA guidelines.
IGF-1 LR3 (Insulin-like Growth Factor-1 Long R3) is an 83-amino acid synthetic analog of native IGF-1, engineered with two specific modifications — an arginine substitution at position 3 and a 13-amino acid N-terminal extension — that reduce its binding to insulin-like growth factor binding proteins (IGFBPs) by approximately 1000-fold. The result is a research compound with an effective half-life of approximately 20–30 hours compared to native IGF-1's 12–15 minutes, making IGF-1 LR3 the standard tool for studying IGF-1 receptor signaling in cell culture and in vivo models where rapid clearance would otherwise confound results.
By: Palmetto Peptides Research Team | Date: March 11, 2026
For research purposes only. Not intended for human or veterinary use. Not for human consumption.
Last Updated: March 17, 2026 | Reading Time: Approximately 5 minutes | Author: Palmetto Peptides Research Team
Quick Answer
IGF-1 LR3 (Insulin-like Growth Factor-1 Long R3) is an 83-amino acid synthetic analog of native IGF-1, engineered with two specific modifications — an arginine substitution at position 3 and a 13-amino acid N-terminal extension — that reduce its binding to insulin-like growth factor binding proteins (IGFBPs) by approximately 1000-fold.
How Do the LR3 Modifications Change IGF-1's Pharmacokinetics?
The two structural modifications in IGF-1 LR3 address the central pharmacokinetic limitation of native IGF-1 — its near-immediate sequestration by IGFBPs 1–6, present in high concentrations in both serum and tissue interstitium.
Modification 1 — Arginine substitution at position 3 (R3):
Native IGF-1 has glutamic acid (Glu) at position 3. Substituting arginine (Arg) changes the charge environment at the N-terminal region, significantly disrupting the binding interface for IGFBPs 1, 2, and 3 — the primary binding proteins that sequester native IGF-1.
Modification 2 — 13-amino acid N-terminal extension:
A 13-residue extension (Met-Ala-Glu-Ala-Pro-Ala-Glu-Ala-Ser-Gly-Gly-Gly-Pro) is added to the N-terminus, providing additional steric interference with IGFBP binding while leaving the C-domain receptor binding region (which engages IGF-1R) structurally intact.
Together, these modifications reduce IGFBP binding affinity by ~1000-fold compared to native IGF-1, allowing IGF-1 LR3 to circulate in free, bioavailable form for 20–30 hours rather than minutes.
What Signaling Pathway Does IGF-1 LR3 Activate?
IGF-1 LR3 binds the IGF-1 receptor (IGF-1R), a transmembrane receptor tyrosine kinase (RTK) encoded by the IGF1R gene on chromosome 15q26.3. Upon binding, IGF-1R undergoes transphosphorylation at tyrosine residues Y1135/Y1136 (activation loop), initiating the canonical anabolic signaling cascade:
IGF-1R → IRS-1/IRS-2 phosphorylation → PI3K activation → PIP₃ → Akt (PKB) activation → mTORC1 signaling
This PI3K/Akt/mTOR axis is associated with:
- Cell survival and anti-apoptotic signaling (Akt phosphorylation of BAD, FOXO transcription factors)
- Protein synthesis initiation (mTORC1 → S6K1 and 4EBP1 phosphorylation)
- Cell cycle progression (cyclin D1 upregulation, CDK4 activation)
- Glucose uptake (GLUT4 translocation in muscle cell models)
IGF-1R also signals through the MAPK/ERK pathway (Ras → Raf → MEK → ERK1/2), associated with cell proliferation and differentiation responses.
What Research Applications Is IGF-1 LR3 Used For?
IGF-1 LR3 is primarily a cell biology and molecular research tool, valued for maintaining sustained IGF-1R activation without the constant media supplementation required for native IGF-1.
Skeletal muscle cell research: In primary myoblast and satellite cell culture models, IGF-1 LR3 is used to study myogenic differentiation, myotube formation, and anabolic signaling. Satellite cells (muscle stem cells, marked by PAX7 expression) respond to IGF-1R activation with proliferative expansion and subsequent differentiation — a research model for studying muscle regeneration biology.
Cell proliferation and survival models: Used in cancer biology research to study IGF-1R-mediated survival signaling in tumor cell lines, where the PI3K/Akt pathway is frequently dysregulated.
In vitro advantage: Cell culture media contains IGFBP-secreting cells that would rapidly sequester native IGF-1. IGF-1 LR3's reduced IGFBP binding allows it to be added once at experiment start and maintain active IGF-1R engagement throughout a typical 12–72 hour experimental window.
How Does IGF-1 LR3 Differ from Native IGF-1 and Growth Hormone?
| Compound | Receptor | Half-Life | IGFBP Binding | Primary Research Use |
|---|---|---|---|---|
| Native GH | GHR | ~15–30 min | N/A | Upstream GH axis signaling |
| Native IGF-1 | IGF-1R | ~12–15 min (free) | High (~99% bound) | Endogenous IGF-1R baseline |
| IGF-1 LR3 | IGF-1R | ~20–30 hours | ~1000x reduced | Sustained IGF-1R research without IGFBP interference |
Frequently Asked Questions
Q: What are IGFBPs and why do they matter for IGF-1 research?
A: IGFBPs (1–6) are carrier proteins that bind IGF-1 in circulation and tissue. Under normal conditions, ~99% of circulating IGF-1 is IGFBP-bound and cannot activate IGF-1R. Native IGF-1's short effective half-life in research settings is primarily a function of this IGFBP sequestration.
Q: Why is a 20–30 hour half-life experimentally significant?
A: It spans the typical in vitro experimental window (12–72 hours). Native IGF-1 in serum-containing media would need replenishment every hour to maintain a sustained signal. IGF-1 LR3 added once at experiment start maintains active IGF-1R engagement throughout, dramatically simplifying experimental design.
Q: Does IGF-1 LR3 bind the insulin receptor (IR)?
A: IGF-1 LR3 has some cross-reactivity with the insulin receptor, as IGF-1R and IR share structural homology. This cross-reactivity is lower than native IGF-1, but researchers working with insulin-sensitive cell lines should account for potential IR co-activation at higher concentrations.
Q: What is the mTOR pathway and why is it relevant?
A: mTORC1 is activated downstream of Akt and phosphorylates S6K1 and 4EBP1 — key regulators of ribosome biogenesis and mRNA translation initiation. IGF-1 LR3's ability to sustain PI3K/Akt/mTORC1 activation makes it a key tool in mTOR pathway research in muscle cell, cancer cell, and metabolic biology models.
Q: Is IGF-1 LR3 the same as mechano growth factor (MGF)?
A: No. MGF (IGF-1Ec) is a splice variant of the IGF1 gene produced locally in muscle in response to mechanical loading. IGF-1 LR3 is a synthetic analog of the mainstream liver-produced IGF-1 isoform (IGF-1Ea), not of MGF.
Explore Palmetto Peptides Research Compounds
All products are research-grade, COA verified, and intended for laboratory research use only.
Related research: IGF-1 LR3 complete research guide, hexarelin GH research, and sermorelin growth hormone research.